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ABSTRACT
A relationship between viral infections and the simultaneous or subsequent development of allergic inflamma-
tion has often been observed in various clinical situations. Recent studies suggest an intimate relationship be-
tween reactivations of herpesviruses including human herpesvirus 6 (HHV-6) and the development of a severe
systemic hypersensitivity reaction referred to as drug-induced hypersensitivity syndrome (DIHS).This syn-
drome has several important clinical features that cannot be solely explained by drug antigen-driven oligoclonal
expansion of T cells: they include paradoxical worsening of clinical symptoms after discontinuation of the
causative drug. In view of the similarity to GVHD or immune reconstitution syndrome (IRS) in clinical manifesta-
tions and emergence of viral infections, the clinical symptoms observed during the course of DIHS and GVHD
are likely to be mediated by antiviral T cells that can cross-react with the drug and alloantigens, respectively. In
considering common intrinsic properties of the causative drugs to potentially induce immunosuppression, re-
constitution of a valid immune response to these viruses, which is typically observed in IRS, may be the most
crucial process that takes place after withdrawal of the causative drug in patients with DIHS. Thus, this syn-
drome should be regarded as a reaction induced by a complex interplay among several herpesviruses (EB vi-
rus, HHV-6, HHV-7, and cytomegalovirus), antiviral immune responses, and drug-specific immune responses.
This review includes discussion of the pathomechanism, the clinical symptoms, laboratory findings, pathologi-
cal findings and therapy．
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INTRODUCTION
A large body of evidence clearly shows that infections
do play a role in the development of various allergic
diseases, although the exact nature of their contribu-
tion is largely unknown.1-3 Do they directly induce
immune cell cross-reactivity with drug-modified host
antigens? Alternatively, do they represent merely the
trigger that sets off an otherwise subliminal allergy
through the action of proinflammtory cytokines ?
Given their potential to activate innate and acquired
immune responses, investigators have become very
interested in the relationship between viral infections
and allergic inflammation. For instance, a relationship
between viral infection and the simultaneous or sub-
sequent development of drug eruptions has been
often observed in the clinical situation; and ampicillin
rash during infectious mononucleosis and an in-
creased risk for developing drug eruptions in AIDS
are perhaps the best known examples of the relation-
ship.4,5 However, although a number of viruses have
been reportedly associated with drug eruptions, no
convincing evidence has linked a single viral agent
with the subsequent risk of developing one disease
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Fig. 1A Face of patient on his initial presentation 
demonstrates slight erythema.
Fig. 1B Patient
,
s face on admission three days after his 
initial presentation demonstrates edema, erythema studded 
with smal pustules, and lymphademophy despite discon-
tinuation of the causative drug.
Fig. 2 Patient
,
s chest and abdomen with confluent purpu-
ric erythematous rash on admission, three days after discon-
tinuation of the causative drug.
Table 1 Drugs frequently causing DIHS/DRESS
・ Dapsone・ Carbamazepine
・ Salazosulfapyridine・ Phenytoin
・ Alopurinol・ Phenobarbital
・ Minocycline・ Mexiletine
outcome．
Nevertheless, recent studies including ours6,7 sug-
gest an intimate relationship between human herpes-
virus 6 (HHV-6) and the development of a severe sys-
temic hypersensitivity reaction referred to as drug-
induced hypersensitivity syndrome (DIHS) or drug
reaction with eosinophilia and systemic symptoms
(DRESS).8 In this review, we focus on the clinical
symptoms of DIHSDRESS and the possible etiologic
role of herpes viruses including HHV-6 in the devel-
opment of this syndrome．
CLINICAL SYMPTOMS
DIHSDRESS usually occurs 3 weeks to 3 months af-
ter starting therapy with a limited number of drugs:
they include carbamazepine, phenytoin, phenobarbi-
tal, dapsone, mexiletine, salazosulfapyridine, allopuri-
nol , and minocycline (Table 1).9 Cross-reactivity
among these drugs has been frequently reported, be-
cause phenytoin, phenobarbital, and carbamazepine
are metabolized to hydroxylated aromatic compound
and arene oxides are suggested intermediates in the
reaction.10 DIHSDRESS has no age or sex predilec-
tion. The delayed onset in relation to introduction of
the causative drug is one of the important features of
DIHSDRESS that can be distinguished from other
types of drug eruptions．
This syndrome commonly begins with a fever
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Table 2 Diagnostic criteria for DIHS/DRESS
1. Maculopapular rash developing＞3 weeks after starting 
therapy with a limited number of drugs
2. Lymphadenopathy
3. Fever (＞38°C)
4. Leukocytosis (＞10×109/L)
　a. Atypical lymphocytosis
　b. Eosinophilia
5. Hepatitis (ALT＞100 U/L)
6. HHV-6 reactivation
The diagnosis is confirmed by the presence of five of the six cri-
teria above
shortly followed by a maculopapular rash, which is
usually pruritic, and variable degrees of lymphadeno-
pathy. The temperature ranges from 38℃ and 40℃
with spikes that usually generate a concern of an un-
derlying infection. The spiking fever often persists
even for weeks despite discontinuation of the offend-
ing drugs. Initially, the upper trunk, face, upper ex-
tremities are affected and followed by involvement of
lower extremities. Periorbital , facial or neck edema
with pinhead-sized pustules is one of the characteris-
tic features of DIHSDRESS at the early stage (Figs.
1,2). The rash often generalizes into a severe exfolia-
tive dermatitis or erythroderma. The severity of dis-
eases at onset provides only a guide to prognosis and
is not absolute. There is usually no mucocutaneous
involvement, which helps distinguish DIHSDRESS
from other forms of severe drug eruptions, such as
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN)．
Tender lymphadenopathy can be seen in most pa-
tients early in the illness, affecting predominantly cer-
vical nodes or generalized. Bilateral swelling of sali-
vary glands with severe xerostomia is frequently ob-
served at first visit. These finding suggest that reacti-
vation of mumps virus may occur before onset of this
syndrome. Hepatomegaly accompanied by splenome-
galyis a common finding. The onset of these symp-
toms is highly variable; usually patients develop two
or three features of symptoms followed by a step-wise
development of other symptoms (Table 2). In many
severe cases, these symptoms continue to deteriorate
or several flare-ups can be seen even for weeks after
stopping the offending drug. Interestingly, the more
severe reactions often occur 3 days after withdrawal
of the causative drug (Fig. 1A vs 1B). Such variability
in the presentation and course of clinical symptoms
allows for a delay in diagnosis, which can lead to sig-
nificant morbidity．
Involvement of other organs varies, depending on
the drug: allopurinol-induced DIHSDRESS has more
frequent renal involvement,11 whereas there appears
to be a higher risk of liver involvement in phenytoin
or dapson-induced disease . 12 Other features of
DIHSDRESS include pneumonitis, coronary artery
thrombosis , thyroiditis , rhabdomyolysis , encephali-
tis,13-15 and diabetes mellitus.16 Depending on the
sites and severity of organ damages, various clinical
symptoms would develop at various time points after
onset. Nevertheless, in most cases their development
is clinically silent and may be recognized only
months or years later . In this regard, we have re-
cently seen patients with DIHSDRESS who devel-
oped limbic encephalitis and the syndrome of inap-
propriate secretion of antidiuretic hormone (SIADH)
long after resolution of rashes. We have also seen pa-
tients with DIHSDRESS who developed viral menin-
gitis and herpes zoster 1―2 months after resolution of
rashes. Thus, in the later phase, after an undefined
period of critical illness of days to weeks, various or-
gan failures will emerge. Despite withdrawal of the of-
fending drug, resolution of symptoms in one organ is
often followed by a step-wise development of such or-
gan system failures (Fig. 3).
LABORATORY FINDINGS
Leukocytosis with atypical lymphocytes and eosino-
philia of various degrees is also a prominent feature
of this syndrome. Nevertheless, leukopenia and lym-
phopenia have been also reported17 and they occa-
sionally precede leukocytosis. Our analyses showed
that atypical lymphocytes predominantly consist of
activated CD8+ T cells.16 The eosinophilia may often
be delayed for 1 to 2 weeks and occur even after ele-
vations in liver enzyme return to baseline. The true
frequency of eosinophilia may actually be lower (～
60%) than previously reported．
Liver abnormalities occur in up to 70% of patients
and are characterized by a marked increase in serum
alanine aminotransferase value. Severe hepatitis por-
tends a prolonged course characterized by multiple
exacerbations and remissions of both rash and liver
disease.18,19 The hepatitis is usually anicteric; but if it
is icteric, it tends to have a poorer prognosis.20 Al-
though the bilirubin may be normal at presentation,
hyperbilirubinemia can develop even after the causa-
tive drug is discontinued . 12 Elevations in liver en-
zymes usually continue to persist for several days af-
ter discontinuation of the offending drug. The mortal-
ity from DIHSDRESS can be approximately 20% and
has been correlated with the degree of hepatic or re-
nal involvement．
As we previously reported,21 a dramatic decrease
in serum IgG, IgA, and IgM levels is typically ob-
served at onset and the lowest IgG, IgA, or IgM lev-
els are usually detected several days after withdrawal
of the offending drug. Thus, serum IgG levels seem
to continue to decrease for at least several days after
drug therapy is discontinued. Immediately after the
nadir in the decrease, the overshoot in IgG levels is
transiently observed within 1 to 2 weeks and they fi-
nally return to normal on full recovery . Another
Drug-induced hypersensitivity syndrome
Allergology International Vol 55, No1, 2006 http:www.jsaweb.jp 3
Fig. 3 The clinical course of DIHS/DRESS. This syndrome usualy begins 
with a fever shortly folowed by a maculopapular rash ＞3 weeks after start-
ing therapy with a limited number of drugs. Patients usualy develop two or 
three features of symptoms folowed by a step-wise development of other 
symptoms. These symptoms continue to deteriorate or several flare-ups can 
be seen even for weeks after stopping the ofending drug. Despite such a 
wide variety of clinical symptoms, HHV-6 reactivation can be detected at the 
certain timing, 3 weeks after withdrawal of the causative drug.
Drug 3wk＜
Eruption
Ig
B cells
NK cells
Fever
Lymphadenosis
Hepatitis
Eosinophilia
HHV-6
DNA HHV-6 Ab？
Fig. 4 Schematic figure ilustrating the relationship 
among viral loads, anti-viral immune responses and clinical 
symptoms before and after discontinuation of the causative 
drug in DIHS/DRESS. Although a strong immune response 
to viruses is presumably beneficial in reducing viral loads, it 
may also have harmful consequences.Harmful aspects of 
this immune response are reflected in the clinical symp-
toms of DIHS/DRESS.
Drug
Viral load
Time
Clinical symptoms
Anti-viral immune response
unique feature of this syndrome is unexplained cross-
reactivity to multiple drugs with structures different
from the offending drug which are used after onset of
the symptoms．
Although close clinical similarities between DIHS
DRESS and infectious mononucleosis suggested a vi-
ral etiology, previous attempt to prove this etiology
have failed; this is because previous studies ruled out
the possibility that EB virus, cytomegalovirus (CMV),
and hepatitis viruses could have produced the clinical
syndrome or laboratory findings, solely based on se-
rologic analyses. In this regard, we and Hashimoto’s
group reported an intimate relationship between
HHV-6 reactivation and the development of this syn-
drome.6,7 This would be the first example, in which
the relationship between a single viral agent and the
subsequent risk of developing one disease outcome
has been convincingly demonstrated . It should be
kept in mind, however, that HHV-6 reactivation as evi-
denced by the rise in HHV-6 IgG titers and HHV-6
DNA levels occurs generally 2―3 weeks after the on-
set of rashes in the vast majority of patients with
DIHSDRESS (Fig. 3). One may suppose, therefore,
that HHV-6 reactivation is a consequence of cell acti-
vation occurring during the course of drug eruptions.
Nevertheless, because HHV-6 reactivation can be de-
tected in the vast majority of patients with DIHS
DRESS but not in other drug eruptions in Japan, this
becomes a specific and sensitive diagnostic test to
correct identification of all patients with this syn-
drome. This appears to be a gold standard test for
DIHSDRESS in Japan, which helps to confirm the
identification of this syndrome. Recent studies includ-
ing our own have also demonstrated that other
herpesviruses, CMV, EBV, and HHV-7, can be se-
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quentially reactivated during the course of this syn-
drome.6,26-28 Based on these findings, we have pro-
posed the concept that various herpes viruses may re-
activate in sequential order during the course of
DIHSDRESS.29
To prove hypersensitivity to the causative drug ,
confirmatory testing such as patch tests and lympho-
cyte transformation tests (LTT) is often performed.
The LTT is laboratory-based in vitro technology that
is most widely available for the assessment of drug-
reactive T cells.22 Although these in vivo and in vitro
tests are consistently positive in the vast majority of
patients with DIHSDRESS and negative in controls,
contradictory results can be reported when per-
formed during the acute stage23-25: false negative re-
actions are observed due to the early timing. Positive
reactions can be consistently observed when tests are
performed after remission, usually 4―6 weeks after
onset. In particular, LTT become positive at least 4
weeks after onset and strong positive reactions can
be observed even >1 year after discontinuation of the
causative drug, a finding never observed in other se-
vere drug eruptions, such as SJS. Considering the
strong positivity long after resolution of the lesions,
LTT appears more reliable and less cumbersome
than patch testing, although the reported sensitivity
of both tests are comparable．
PATHOLOGICAL FINDINGS
The common pathological findings are superficial
perivascular lymphocytic infiltrates and some ex-
travasated erythrocytes or eosionophils . A dense ,
band-like lymphocytic infiltrates with epidermotro-
pism, suggestive of lymphoma, can be seen in some
patients. In some patients, there is liquefaction de-
generation of the basal cell layer with a lichenoid infil-
trate, compatible with severe drug eruptions. How-
ever, this lichenoid infiltrates with apoptotic keratino-
cytes, a finding frequently seen in SJS and TEN, are
relatively atypical findings in DIHSDRESS. Immuno-
histochemical stains demonstrate a predominance of
T cells．
In our first report on HHV-6 in a patient with
DIHSDRESS , we detected high levels of HHV-6
genome and viral antigens on infiltrating cells in the
skin lesions taken at the early stage,6 which suggests
an etiological role of this microorganism. However,
the presence of HHV-6 DNA in the lesions cannot be
taken as proof of causation of the lesions; and we
could not exclude the possibility that the detection of
HHV-6 DNA in the cellular infiltrates could merely re-
flect a propensity for viral recurrence to lead to infec-
tion of these cells．
PATHOMECHANISMS
Although several theories have been proposed, the
pathomechanisms of DIHSDRESS remains largely
unknown. So far, no satisfying explanation for diver-
sity of the clinical symptoms as described above has
been offered. The results of the patch tests and LTT
indicate that drug-specific T cells are the driving
force behind this syndrome . 6,21,30-32 However , not
easily reconciled with drug antigen-driven oligoclonal
expansion of T cells are clinical features, such as its
delayed onset, frequent deterioration or several flare-
ups after withdrawal of the causative drugs, multior-
gan involvement, and unexplained cross-reactivity to
multiple drugs used after onset of rashes. An alterna-
tive theory is that toxic oxidative metabolities of these
drugs generated under certain circumstances bind to
tissue macromolecules thereby acting as haptens
stimulating CD4+ and CD8+ T cells.10
We have recently suggested an important role of
herpesvirus reactivations sequentially occurring be-
fore and during the course of this syndrome in the
development of DIHSDRESS29: reactivation of latent
herpesviruses, such as EBV, may be initially induced
far before onset of clinical symptoms and strong im-
mune responses to the reactivations might have the
dual effects of reducing viral loads and developing
clinical symptoms. According to this theory, clinical
symptoms are likely mediated by an expansion of
virus-specific and nonspecific T cells in response to
the reactivations of these viruses. Indeed, in EBV-
induced infectious mononucleosis, an increase in sys-
temic viral loads is not reflected in symptom severity;
the severity is rather a reflection of massive expan-
sion of T cells. In this regard, we for the first time re-
ported a patient who experienced severe skin rash as-
sociated with sequential reactivations of various
herpesviruses . 29 Until now , however , longitudinal
analyses of herpesvirus reactivations during the
course of the syndrome have been predominantly
performed by serologic tests, but not by PCR-based
detection of viral DNA, which is obscured by uncer-
tainty about the rise in antibody titers to viruses in
this setting : reactivations of herpesviruses at the
early phase cannot be reflected in antibody titers at
the early phase because a dramatic decrease in Ig
production has been reported to occur at that time.21
We therefore performed real-time PCR to detect and
quantify viral DNA, using blood samples sequentially
obtained from patients with DIHSDRESS after onset
of rashes．
Although the order of herpesviruses sequentially
reactivated was not exactly the same in patients with
DIHSDRESS examined, our PCR analyses showed
that various herpesviruses can sequentially reactivate
during the course of this syndrome (Kano Y et al .
Manuscript submitted). The cascade of virus reactiva-
tion initiated by HHV-6 or EBV extended, with some
delay, to HHV-7 and eventually to CMV. Surprisingly,
this cascade of sequential herpesvirus reactivations
observed in DIHSDRESS is quite similar to that ob-
served in graft-versus-host disease (GVHD).33,36 In
view of the similarity between DIHSDRESS and
Drug-induced hypersensitivity syndrome
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GVHD with regard to the clinical manifestations, the
highly variable waxing and waning nature of the clini-
cal manifestations occurring in different organs de-
spite discontinuation of the offending drug could be
explained by sequential reactivations of these herpes-
viruses ; nevertheless , sequential reactivations of
these viruses were not always associated with evi-
dence of overt clinical symptoms. Interestingly , re-
cent studies have provided strong suggestive evi-
dence for a role of viral infections in the emergence
of alloreactive T cells and the development of
GVHD.33-35 In the setting of GVHD, it has been hy-
pothesized that activation of donor-derived antiviral T
cells by alloantigens or bystander activation of the an-
tiviral T cells by massive cytokine production are re-
sponsible for the development of GVHD. In support
of this hypothesis , herpesvirus genome can be de-
tected at high frequency coincident with the clinical
symptoms, suggesting that virus-driven clonal expan-
sions of alloreactive T cells that may have originally
generated to deal with herpesviruses are involved in
initiating GVHD37: if so, the severity of clinical symp-
toms in DIHSDRESS as well as GVHD would be de-
termined by the magnitude of expansions of antiviral
T cells. These similarities to GVHD, together with
the ability of HHV-6 and HHV-7 to reactivate heterolo-
gous viruses,38,39 led us to consider the possibility
that these herpesviruses might be functionally linked
in vivo, the reactivation of one leading to the reactiva-
tion of the other, thus explaining the ambiguity in the
apportioning their role . These considerations raise
the possibility that the clinical manifestations origi-
nally attributed to CMV or EBV can be ascribed to
HHV-6 or HHV-7．
Thus, by analogy with the similarities to GVHD,
the clinical symptoms observed during the course of
DIHSDRESS are likely to be mediated by antiviral T
cells that can cross-react with the drugs but not solely
by drug-driven oligoclonal expansions of drug-
specific T cells. This scenario could provide answers
to many questions arising on DIHSDRESS: why fre-
quent deterioration can be seen after withdrawal of
the offending drug; why multiple organs are involved
in a sequential order ; and why unexpected cross-
reactivity to multiple drugs with different structures
can be seen despite a very limited number of drugs
responsible for initiating this syndrome. Our unpub-
lished finding that LTT to the offending drug was
negative during the development of rash and became
strong positive after recovery (Manuscript in prepara-
tion) could be also explained by this scenario , be-
cause these herpesviruses could induce and maintain
a potent specific memory T-cell response for long
times after recovery from DIHSDRESS due to their
common properties of ubiquitous prevalence in hu-
man populations and the capacity to grow in lym-
phoid cells．
Assuming that antiviral T cells are primarily in-
volved in the development of DIHSDRESS , the
question arises why viral genome was only detected
2―3 weeks after onset of this syndrome but not at the
early stage. In this regard, of note are previous re-
ports indicating that causative drugs shown to induce
DIHSDRESS have in common intrinsic properties to
potentially cause immunosuppression. 21 In view of
these properties of these drugs, our finding that para-
doxical worsening of clinical and laboratory parame-
ters was often observed after discontinuation of the
causative drug in many patients with
DIHSDRESS6,21 can be alternatively interpreted as
follows: discontinuation of these drugs could be asso-
ciated with rapid restoration of virus-specific cellular
and humoral responses that would reduce viral loads
on the one hand but cause tissue damage on the
other (Fig. 4). Thus, unrecongnized reactivations of
herpesviruses would be already present by protracted
administration of these drugs before onset of this
syndrome and this reactivation may be only un-
masked by rapid restoration of anti-viral immune re-
sponses due to discontinuation of these drugs. In sup-
port of this possibility , many cases with various
pathogens-associated immune reconstitution syn-
drome (IRS) have been reported to occur in HIV-
infected individuals after administration of potent an-
tiretroviral therapy or withdrawal of immunosuppres-
sive agents that can cause improved anti-viral im-
mune responses. 40 Unlike the widely held notion ,
clinical symptoms in DIHSDRESS are likely to be
mediated by rapidly restored anti-viral immune re-
sponses, just like those in IRS, but not by viruses
themselves. Thus, our finding of no detection of viral
genome at the time of clinical onset 21 can be ex-
plained by assuming that virus clearance may take
place upon reconstitution of a valid immune response
after withdrawal of the causative drug in patients with
DIHSDRESS．
TREATMENT
Early recognition of this syndrome is the most impor-
tant step in treatment and is essential in improving
patient outcomes, because many physicians are not
familiar with this syndrome. Empirical treatment with
antibiotics or NSAIDs should not be done during the
acute period, which may confuse or worsen the clini-
cal picture probably due to unexplained cross-
reactivity．
The mainstay of treatment is systemic corticoster-
oids . Rapid resolution of rashes and fever occurs
within several days after starting systemic corticoster-
oids: the usual dosage is prednisolone 40―60 mgday.
Nevertheless, this treatment has not been formally
studied in randomized placebo-controlled trials; how-
ever, this trial is difficult to perform due to the life-
threatening nature of this syndrome. Systemic corti-
costeroids need to be tapered over 6―8 weeks to pre-
vent the relapse of various symptoms of this syn-
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drome. Marked deterioration of various symptoms is
often observed with accidental discontinuation or too
rapid tapering of corticosteroids. We therefore rec-
ommend that all patients with DIHSDRESS be hos-
pitalized even if the initial presentation is mild . If
symptoms deteriorate despite systemic corticoster-
oids, other options used successfully in small series
of patients include pulsed intravenous methylpredni-
solone (30 mgkg for 3 days), intravenous immuno-
globulin G (IVIG), and plasmapheresis, or a combina-
tion of these. It should be further noted that these im-
munosuppressive therapies may enhance the risk of
infectious complications and sepsis. Mild cases may
recover from this syndrome by supportive care with-
out the need of systemic corticosteroids within few
weeks. Even in these mild cases, however, hepatic
and renal value should be monitored closely and ap-
propriate testing should be performed to exclude in-
volvement of specific organs, such as lungs, heart ,
and thyroid, known to be affected by this syndrome.
In particular, because hypothyroidism may appear for
several months after the acute illness is completely
resolved, thyroid function should be monitored care-
fully for at least several months after resolution of the
acute illness．
CONCLUSION
Although great strides have been made in our under-
standing of the natural history and pathomechanism
(s) of this syndrome, many questions remain unan-
swered. DIHSDRESS should not be regarded as a
reaction solely mediated by drug antigen-driven oli-
goclonal expansion of T cells, but as a reaction in-
duced by a complex interplay among viruses, antiviral
innate and adaptive immune responses , and , of
course , drug-specific immune responses . Thus ,
DIHSDRESS provides a fascinating model for study-
ing the complex interplay leading from viral infection
to the development of allergic diseases．
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